Improved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience

İbrahim Bayram; Gülay Sezgin; Ayşe Özkan; Serhan Küpeli; Atila Tanyel,i

Makale detayları

Improved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience

Yazarlar:

İbrahim Bayram | Gülay Sezgin | Ayşe Özkan | Serhan Küpeli | Atila Tanyel,i

Yayıncı:

Cukurova University

Ana Başlıklar:

Çocuk Hematolojisi ve Onkolojisi

Dergi:

Cukurova Medical Journal Vol.50 Issue 2, pp.506-518

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351444

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Abstract Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia ALL patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I n234 received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II n139 received a modified BFM-95 protocol TRALL-2000 between January 2001 and March 2007. Group III n199 received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 60.1 were boys and 228 39.9 were girls. The 10-year overall survival OS rates were 30, 53, and 73 for Groups I, II, and III, respectively. Event-free survival EFS rates were 27, 40, and 64. In Group III, the 10-year OS was 92 for the standard-risk group SRG, 71 for the medium-risk group MRG, and 59 for the high-risk group HRG; the corresponding EFS rates were 72, 68, and 49. Among Group III patients, the 10-year OS was 64 for girls and 78 for boys. The OS for B-cell ALL was 71, and for T-cell ALL, 78. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.

 Abstract Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia ALL patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I n234 received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II n139 received a modified BFM-95 protocol TRALL-2000 between January 2001 and March 2007. Group III n199 received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 60.1 were boys and 228 39.9 were girls. The 10-year overall survival OS rates were 30, 53, and 73 for Groups I, II, and III, respectively. Event-free survival EFS rates were 27, 40, and 64. In Group III, the 10-year OS was 92 for the standard-risk group SRG, 71 for the medium-risk group MRG, and 59 for the high-risk group HRG; the corresponding EFS rates were 72, 68, and 49. Among Group III patients, the 10-year OS was 64 for girls and 78 for boys. The OS for B-cell ALL was 71, and for T-cell ALL, 78. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.

 Abstract Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia ALL patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I n234 received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II n139 received a modified BFM-95 protocol TRALL-2000 between January 2001 and March 2007. Group III n199 received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 60.1 were boys and 228 39.9 were girls. The 10-year overall survival OS rates were 30, 53, and 73 for Groups I, II, and III, respectively. Event-free survival EFS rates were 27, 40, and 64. In Group III, the 10-year OS was 92 for the standard-risk group SRG, 71 for the medium-risk group MRG, and 59 for the high-risk group HRG; the corresponding EFS rates were 72, 68, and 49. Among Group III patients, the 10-year OS was 64 for girls and 78 for boys. The OS for B-cell ALL was 71, and for T-cell ALL, 78. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.

 Öz Amaç: Ocak 1990 ile Eylül 2021 tarihleri arasında kliniğimize başvuran ALL hastalarına uygulanan tedavi protokolleri karşılaştırıldı. Gereç ve Yöntem: Hastaların dosyaları retrospektif olarak incelendi. Veriler Haziran 2022e kadar alındı. Hastalar tedavi protokollerine göre 3 gruba ayrıldı. Grup I n234; Ocak 1990-Ocak 2001 tarihleri arasında BFM-85-90-95 kullanılan hastalardan, Grup II n139; Ocak 2001-Mart 2007 tarihleri arasında modifiye BFM-95 protokolü TRALL-2000 adı verildi kullanılan hastalardan, Grup III n199; 2007den itibaren tarafımızca modifiye edilmiş bu TRALL-2000 protokolü kullanılan hastalardan oluşturuldu. Bulgular: Hastaların 344ü 60,1 erkek, 228i 39,9 kız idi. Grup Ide 10 yıllık genel sağkalımın GS 30, grup IIde 53 ve grup IIIte 73 olduğu ve olaysız sağkalımın EFS sırasıyla 27, 40 ve 64 olduğu bulundu. Ayrıca, Grup III hastalarını risklerine göre analiz ettiğimizde; standart risk grubundaki SRG hastalarda 10 yıllık GS 92, orta risk grubundaki MRG hastalarda 71 ve yüksek risk grubundaki HRG hastalarda 59 idi. 10 yıllık EFS sırasıyla 72, 68 ve 49 idi. Ayrıca, grup IIIteki kız hastaların 10 yıllık GSsi 64, erkeklerde ise 78 olarak bulundu. Benzer şekilde, B hücreli ALL için 10 yıllık GS 71 ve T hücreli ALL için 78 olarak bulundu. Sonuç: Grup III hastalarının GS ve EFSsi önceki protokolleri kullanan hastalara kıyasla anlamlı derecede yüksek idi. Ayrıca, literatürün aksine, grup IIIteki T hücreli ALL hastalarının GS ve EFS oranları B hücreli ALL hastalarından daha iyi idi ve erkeklerdeki sağkalım kızlara göre daha uzun idi.

Makale detayları

Improved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience

Yazarlar:

İbrahim Bayram | Gülay Sezgin | Ayşe Özkan | Serhan Küpeli | Atila Tanyel,i

Yayıncı:

Cukurova University

Ana Başlıklar:

Çocuk Hematolojisi ve Onkolojisi

Dergi:

Cukurova Medical Journal Vol.50 Issue 2, pp.506-518

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351444

pISSN:

2602-3032

Acute lymphoblastic leukemia

chilhood

chemotherapy

BFM protocolsAkut lenfoblastik lösemi

çocukluk çağı

kemoterapi

BFM protokolleri

Sayı

Makale detayları

Yazarlar: İbrahim Bayram | Gülay Sezgin | Ayşe Özkan | Serhan Küpeli | Atila Tanyel,i

Yayıncı: Cukurova University

Ana Başlıklar: Çocuk Hematolojisi ve Onkolojisi

Dergi: Cukurova Medical Journal Vol.50 Issue 2, pp.506-518

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001351444

pISSN: 2602-3032

Sayı

Yazarlar:

İbrahim Bayram | Gülay Sezgin | Ayşe Özkan | Serhan Küpeli | Atila Tanyel,i

Yayıncı:

Cukurova University

Ana Başlıklar:

Çocuk Hematolojisi ve Onkolojisi

Dergi:

Cukurova Medical Journal Vol.50 Issue 2, pp.506-518

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351444

pISSN:

2602-3032